← Issue №20/
week of Nov 15, 2026/
the whole section, in full
Hepatology, in full.
All 14 Hepatology papers in this issue,
as full cards, ranked by clinical utility. The issue page carries the strongest few;
this is the section, whole.
Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
Hepatologyprospective cohort · n=93,663 · Nov 11, 2026 · Clin Gastro Hep · IF 16.2
New evidencecirrhosisportal hypertensionliver transplantepidemiology
Clinical takeawayThese propensity-matched associations support indication-specific anticoagulant choice in cirrhosis: in AF, DOACs were associated with less bleeding at similar mortality; in DVT/PE or PVT, DOAC initiators had higher mortality and lower transplant access than warfarin initiators.
What it foundAmong 93,663 initiators, DOACs vs warfarin in AF were associated with similar mortality and transplant rates and lower major and non-gastrointestinal bleeding, including intracranial hemorrhage. In DVT/PE and PVT, DOACs were associated with higher mortality (sHR 1.21 [95% CI 1.10-1.34] and 1.43 [1.24-1.65]) and lower transplant rates (sHR 0.25 [0.17-0.38] and 0.23 [0.17-0.32]); gastrointestinal bleeding was higher with DOACs in PVT (sHR 1.26 [1.06-1.50]).
ContextPartly an allocation effect: in a waitlisted cohort (n=284), warfarin-related INR elevation, which inflates MELD, mediated 29% of the transplant-access difference; the authors call for reconsidering INR handling in US transplant allocation.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Tanaka T … Axelrod D · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyrct · n=84 · Nov 12, 2026 · Am J Gastro · IF 9.8
New evidencecirrhosisportal hypertensionvariceal bleeding
Clinical takeawayDabigatran 150 mg twice daily can be considered for recanalizing chronic PVT in Child-Pugh A/B cirrhosis on the strength of this placebo-controlled trial (42 patients per arm); the fewer bleeding events and better CTP and ALBI scores are exploratory.
What it foundComplete recanalization at 12 months: 27/42 (64.3%) with dabigatran 150 mg twice daily vs 9/42 (21.4%) with placebo (p<0.001). Variceal bleeding episodes were fewer (3 vs 12; p=0.008), a clinical-event difference the authors call exploratory.
ContextDOACs are emerging options for PVT in cirrhosis, with uncertain safety and efficacy. Patients had a median CTP score of 8 and 45.2% had prior variceal bleeding; MELD trajectories did not differ between groups.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Meena BL … Sarin SK · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Hepatologyretrospective · n=2,221 · Nov 13, 2026 · J Clin Gastro · IF 2.9
Clinical takeawayThe authors suggest targeting diuretic avoidance and timely postdischarge visits, both expert-recommended process measures; follow-up within 15 days was uncommon (primary care 28%, gastroenterology/hepatology 6%), and the evidence is retrospective.
What it foundAmong 2221 patients with ascites and AKI at Veterans Administration hospitals, diuretic avoidance was associated with AKI resolution (OR 1.14, 95% CI 1.02-1.28), and timely postdischarge visits with primary care (HR 0.53, 95% CI 0.43-0.67) or gastroenterology/hepatology (HR 0.44, 95% CI 0.29-0.66) with lower 90-day mortality.
ContextConfirms expert recommendations for AKI management in cirrhosis, providing evidence linking specific process measures to improved outcomes in hospitalized cirrhosis patients with AKI.
Emergingsuggested applicable standard· International Club of Ascites (ICA) & Acute Disease Quality Initiative (ADQI), "Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting," Journal of Hepatology, 2024ShowHide
Per the 2024 ADQI-ICA joint consensus (which updates the 2015 ICA-AKI criteria referenced in AASLD 2021), in a patient with cirrhosis and ascites: DIAGNOSE HRS-AKI when all of (a) cirrhosis with ascites; (b) AKI by KDIGO/ICA criteria, serum creatinine rise ≥0.3 mg/dL (26.5 µmol/L) within 48h or ≥50% from a baseline known or presumed within the prior 7 days, and/or urine output ≤0.5 mL/kg/h for ≥6h (strong recommendation, grade A); (c) absence of improvement in serum creatinine and/or urine output within 24h following adequate volume resuscitation WHEN CLINICALLY INDICATED, the consensus recommends AGAINST systematic 48h albumin administration as a diagnostic requisite (strong recommendation, grade D), and only where volume status is equivocal is a single fluid challenge (250-500 mL crystalloid, or 1-1.5 g/kg of 20-25% albumin) assessed within 24h; and (d) absence of strong evidence for an alternative primary cause of AKI (e.g., septic shock requiring vasopressors, acute glomerular injury, obstruction, or nephrotoxin-induced AKI) (not graded).…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Per the 2024 ADQI-ICA joint consensus (which updates the 2015 ICA-AKI criteria referenced in AASLD 2021), in a patient with cirrhosis and ascites: DIAGNOSE HRS-AKI when all of (a) cirrhosis with ascites; (b) AKI by KDIGO/ICA criteria, serum creatinine rise ≥0.3 mg/dL (26.5 µmol/L) within 48h or ≥50% from a baseline known or presumed within the prior 7 days, and/or urine output ≤0.5 mL/kg/h for ≥6h (strong recommendation, grade A); (c) absence of improvement in serum creatinine and/or urine output within 24h following adequate volume resuscitation WHEN CLINICALLY INDICATED, the consensus recommends AGAINST systematic 48h albumin administration as a diagnostic requisite (strong recommendation, grade D), and only where volume status is equivocal is a single fluid challenge (250-500 mL crystalloid, or 1-1.5 g/kg of 20-25% albumin) assessed within 24h; and (d) absence of strong evidence for an alternative primary cause of AKI (e.g., septic shock requiring vasopressors, acute glomerular injury, obstruction, or nephrotoxin-induced AKI) (not graded). HRS-AKI is a phenotype specific to advanced cirrhosis and ascites: coexisting CKD, tubular injury or proteinuria do NOT exclude it, and it may coexist with, or be superimposed on, other AKI etiologies rather than requiring pure exclusion. TREAT: immediately on diagnosis start a vasoconstrictor plus 20-25% albumin (strong recommendation, grade A). Terlipressin is first-line, continuous IV infusion 2-12 mg/day, titrated up by ≥2 mg/day every 24h to a maximum 12 mg/day if serum creatinine has not fallen ≥25%; or IV bolus 1-2 mg every 6h, escalated from 1 mg to 2 mg every 6h on that same ≥25% serum-creatinine response threshold, with the 12 mg/day maximum applying only to continuous infusion and not to bolus dosing. If terlipressin is unavailable or contraindicated, norepinephrine (continuous infusion 0.5-3 mg/h, up-titrated 0.5 mg/h every 4h to raise MAP ≥10 mmHg; requires ICU care and a central line) may be more appropriate. Midodrine 7.5-15 mg PO every 8h plus octreotide 100-200 µg SC every 8h with albumin is third-line, considered only if terlipressin is contraindicated AND transfer to ICU for norepinephrine is not possible. Give 20-25% albumin 20-40 g/day with any vasoconstrictor, adjusted daily to volume status and withheld for fluid overload/pulmonary edema. Discontinue vasoconstrictors when serum creatinine returns to within 0.3 mg/dL of baseline, for a severe adverse reaction, if kidney function does not improve after 48h at maximum tolerated dose, if RRT is indicated, or at a maximum of 14 days of therapy (strong recommendation, grade B). Initiation of RRT should be individualized to clinical context and anticipated or observed life-threatening AKI-related complications (best-practice statement) rather than framed strictly as a transplant-bridge measure. Recommend expedited evaluation for liver transplantation following an episode of AKI (best-practice statement); LT in selected patients is the definitive treatment for HRS-AKI regardless of vasoconstrictor response (strong recommendation, grade A), with vasoconstrictors serving as a bridge to transplantation or renal recovery rather than a cure.
New evidenceviral hepatitishepatocellular carcinomaMASLD
Clinical takeawayThe authors propose assessing and correcting metabolic dysfunction as part of CHB care, and including CHB patients in metabolic-therapy trials, so success is defined by liver outcomes, not the virus alone.
What it foundMetabolic dysfunction lowers adult vaccination response compared to non-metabolic dysfunction, enters three of the four WHO treatment eligibility routes (specifics in source), and increases HCC risk during antiviral therapy in CHB patients.
ContextChallenges current CHB care by highlighting the overlooked impact of metabolic dysfunction on treatment eligibility, HCC risk, and outcomes in CHB patients.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases / Infectious Diseases Society of America (AASLD/IDSA), "AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B," Hepatology, 2026ShowHide
…Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
The 2026 AASLD/IDSA guideline addresses six PICO questions only; it states explicitly that all other 2018 AASLD recommendations for CHB management remain applicable, and that screening/diagnosis were out of scope. Baseline evaluation and the standard treatment indications (cirrhosis with detectable HBV DNA; HBeAg-positive immune-active with ALT >2x ULN and HBV DNA >20,000 IU/mL; HBeAg-negative immune-active with ALT >2x ULN and HBV DNA >2,000 IU/mL; prophylaxis for reactivation risk during immunosuppression) derive from the 2018 document, not this update, which lists 'treatment of HBeAg-positive and -negative immune active CHB with ALT >2x ULN', treatment of children, treatment of cirrhosis, low-level viremia, virologic breakthrough, and special populations (transplant, acute HBV, HCV/HDV/HIV coinfection) as topics 'well covered in previous AASLD 2018 Guidance and for which recommendations have not changed'. Preferred agents remain entecavir, TDF, or TAF. THE SIX 2026 RECOMMENDATIONS: (1) PMTCT, for pregnant persons with HBV DNA >200,000 IU/mL at any time point during pregnancy, regardless of HBeAg status, AASLD RECOMMENDS initiating TDF or TAF at gestational week 28 (STRONG recommendation, MODERATE certainty, the only strong recommendation in the guideline); TDF has a more extensive safety record in pregnancy than TAF. Implementation qualifiers: initiate immediately if care is first sought after week 28; initiate at week 16 if infant HBIG will be unavailable (with subsequent infant vaccination); consider earlier initiation when amniocentesis is anticipated (transmission risk is increased with HBV DNA >2,000,000 IU/mL) or when preterm labor risk is high; continue TDF/TAF if already on it, switch entecavir or other agents to TDF/TAF; if treatment was solely for perinatal prophylaxis it may be discontinued at delivery, with HBV DNA and ALT monitored every 1-3 months for up to 6 months for withdrawal flare and treatment reinitiated if ALT >=5x ULN; use TDF or TAF in breastfeeding persons requiring treatment. (2) HORIZONTAL TRANSMISSION, for HBsAg-positive viremic persons not meeting disease-specific treatment indications who are in high-risk scenarios for transmission to others, AASLD SUGGESTS a shared decision-making approach regarding antiviral treatment (CONDITIONAL, VERY LOW certainty). Qualifiers the guideline stresses: the decision weighs exposure risk and the vaccine/immunity status of contacts, favoring treatment if contacts are unvaccinated, vaccine-nonresponsive, immunocompromised, or of unknown vaccine status; persons requesting treatment for prevention may be prescribed it since risks may not be disclosed; explicitly, people with CHB must NOT be restricted in daily activities, contact sports, school, or professional training and must NOT be required to take antivirals because of transmission risk in those settings; routine contact, shared meals, and hugging are not transmission routes (avoid sharing toothbrushes/razors); most healthcare workers with CHB are NOT high-risk, but those performing SHEA Category III exposure-prone procedures may require antivirals (SHEA target HBV DNA <1000 IU/mL); neither CDC nor SHEA requires disclosure to patients or staff; anti-stigma framing is part of the recommendation. (3) IMMUNE-TOLERANT PHASE, defined as HBeAg-positive, HBV DNA >10^7 IU/mL, and normal ALT; AASLD SUGGESTS antiviral therapy for those over age 40 years, OR with significant liver inflammation (grade >=2) or fibrosis (>=F2) on biopsy or noninvasive tests (CONDITIONAL, VERY LOW certainty). For persons under age 40 who are interested in starting treatment earlier, AASLD suggests shared decision-making weighing risk factors and the benefits and risks of treatment. Accurate phase identification requires persistently normal ALT on >=2 measurements >=6 months apart, using ULN 35 U/L (males) and 25 U/L (females). (4) INDETERMINATE ('grey zone') PHASE, the HBeAg-negative indeterminate phase is defined as HBsAg-positive, HBeAg-negative persons whose ALT and/or HBV DNA fall outside the thresholds for HBeAg-negative immune-active CHB (ALT >2x ULN and HBV DNA >2,000 IU/mL) and outside those for inactive CHB (HBV DNA <2,000 IU/mL with normal ALT), comprising predominantly two subgroups, (I) normal (<ULN) or mildly elevated (<2x ULN) ALT with HBV DNA >=2,000 IU/mL, or (II) elevated ALT (>ULN) with HBV DNA <2,000 IU/mL, with ALT interpreted against ULN 35 U/L (males) and 25 U/L (females) and phase assigned on >=2 ALT and HBV DNA measurements over a 6-12 month period; in adults who are HBsAg-positive, HBeAg-negative, without cirrhosis and in the indeterminate phase so defined, AASLD SUGGESTS antiviral therapy using a shared decision-making approach assessing risks and benefits, and re-evaluating that decision at each follow-up visit if treatment has not been initiated (CONDITIONAL, VERY LOW certainty). Decision-relevant factors include fibrosis stage, age, and sex, e.g. age >40, male sex, and low-normal platelets (<180 k/mm3) favor treatment. (5) DISCONTINUATION, in adults with CHB who are HBeAg-negative, without cirrhosis, with sustained undetectable HBV DNA on nucleos(t)ide analogue therapy, AASLD SUGGESTS NOT withdrawing NA therapy until HBsAg loss (CONDITIONAL, VERY LOW certainty). If a patient nonetheless has a strong desire to stop, shared decision-making applies and ALL of the following must be met: no history of advanced fibrosis/cirrhosis, hepatic decompensation (variceal bleed, ascites, encephalopathy, hepatorenal syndrome), HCC, or extrahepatic HBV complications; if HBeAg-positive at treatment start, HBeAg seroconversion to anti-HBe-positive for >=1 year with undetectable HBV DNA >=2 years; if HBeAg-negative at start, undetectable HBV DNA >=2 years; no HIV or HDV coinfection; quantitative HBsAg <100 IU/mL; and willingness to adhere to frequent monitoring. After stopping, monitor ALT and HBV DNA every 1-3 months for 6 months, then every 3 months for 6-12 months, then every 3-6 months. Restart antivirals IMMEDIATELY if HBV DNA >=10,000 IU/mL (4 log IU/mL) at any time regardless of ALT, OR ALT >=5x ULN regardless of HBV DNA, OR total bilirubin >2.5 mg/dL. (6) HCC SURVEILLANCE (all CONDITIONAL, VERY LOW certainty; modality/interval per AASLD 2023 HCC Practice Guidance), Rec 6: after HBsAg loss, continue surveillance in those with cirrhosis, family history of HCC, men who lost HBsAg after age 40, and women who lost HBsAg after age 50. Rec 7: in HBV-HDV coinfection, surveil adults independent of cirrhosis status; in children, individualize because HCC risk in that population is unknown. Rec 8: in HBV-HIV coinfection, surveil men >=18 years and women >=40 years. Rec 9: in HBV-HCV coinfection, AASLD recommends treating HCV and suggests HCC surveillance per HBV mono-infection criteria. Where a person has more than one coinfection, the surveillance recommendation should follow the coinfection carrying the highest associated risk. The guideline notes that most of its recommendations rest on low or very low certainty evidence and that shared decision-making, not uniform policy, is the intended mode of application.
New evidencecirrhosishepatic encephalopathyepidemiology
Clinical takeawaySedating medication use (gabapentinoids, TCAs, benzodiazepines, anticholinergics, non-benzodiazepine hypnotics, antipsychotics, opioids) marks higher fall and hospitalization risk in cirrhosis, with ≥2 drugs associated with about twice the hazard; the authors call for trials of medication review and deprescribing.
What it foundIn 230 patients with cirrhosis, each additional sedating medication was associated with a 30-34% higher hazard of falls (sHR 1.30-1.34) and a 40-48% higher hazard of hospitalization (sHR 1.40-1.48).
ContextProspective multicentre cohort; overt HE reached significance in the MELD-Na and Child-Pugh adjusted model (sHR 1.93, 95% CI 1.03-3.63), and neither nonselective beta-blockers nor diuretics were associated with falls or hospitalization.
Measured against the standard of care· ACG 2026 (Bajaj JS, Jakab SS, Jesudian AB, et al. Am J Gastroenterol 2026;121(3):588-618) / EASL 2022ShowHide
In adults with cirrhosis, hepatic encephalopathy (HE) is a clinical diagnosis.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
In adults with cirrhosis, hepatic encephalopathy (HE) is a clinical diagnosis. It is graded by West Haven (minimal plus grade 1 = covert; grades 2-4 = overt) and made only after other causes of altered mentation are excluded. Routine brain imaging is not needed in a patient with cirrhosis and confusion. Do not routinely check serum ammonia to guide HE treatment (conditional, very low certainty), and do not use ammonia alone to diagnose minimal or covert HE (conditional, very low). Ammonia should not be used to grade overt HE or to titrate therapy, though EASL 2022 notes that a normal level calls the diagnosis into question. For covert or minimal HE, use a single psychometric or neurophysiological test rather than two in combination (conditional, very low). Lactulose is suggested over no treatment for covert or minimal HE (conditional, low), but the evidence is insufficient to recommend routine treatment to prevent overt HE. In every episode of overt HE, search for and treat precipitants: infection, GI bleeding, dehydration or diuretic excess, electrolyte disturbance, constipation, sedatives. Reassess if the patient has not improved within 48-72 h. Lactulose is first-line for overt HE (strong, moderate), titrated to 2-3 soft bowel movements a day, given orally or by enema in grade 3-4. High-volume polyethylene glycol (about 4 L) is suggested as an alternative to lactulose (conditional, low). In acute inpatient overt HE, adding rifaximin to lactulose is suggested over lactulose alone (conditional, low). After a first episode of overt HE, give lactulose as secondary prophylaxis titrated to 2-3 BM/day. Outpatient rifaximin is suggested to prevent recurrence (conditional, low). Adding rifaximin 550 mg twice daily to lactulose is strongly recommended for recurrence while on lactulose (strong, high). If symptoms persist on lactulose plus rifaximin, zinc may be added when blood zinc is low (conditional, very low). Do not restrict protein (conditional, very low). Target protein 1.2-1.5 g/kg/day (strong, moderate) and give a late-evening snack (conditional, very low). Use BCAA supplementation when food alone cannot meet protein needs (strong, moderate). Before elective TIPS in decompensated cirrhosis, start rifaximin 14 days ahead and continue it for at least 6 months, with or without prior overt HE (strong, moderate). Extrahepatic collaterals may be embolized at the time of TIPS to reduce post-TIPS HE (conditional, low). For HE refractory to optimized medical therapy, embolization of a spontaneous portosystemic shunt is suggested in patients with adequate hepatic function and no contraindications (conditional, very low). Post-TIPS refractory HE may warrant TIPS reduction. Refer for transplant evaluation in patients with recurrent or persistent HE. In patients with multiple HE episodes and MELD <15, evaluate candidacy for living-donor liver transplant (conditional, low). Give oral and written advice against driving.
Tapper EB … Serper M · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyrct · n=300 · Nov 11, 2026 · Lancet GH · IF 39.1
Clinical takeawayAwait phase 3 trial results and regulatory approval before considering pemvidutide for MASH patients with F2-F3 fibrosis.
What it foundPemvidutide 1.8 mg reduced liver fat content by 54.7% vs placebo's 8.2% at 48 weeks in MASH patients with F2-F3 fibrosis.
ContextThis extends prior 24-week findings, confirming pemvidutide's efficacy in reducing liver fat in MASH, a condition with limited treatment options. Liver biopsies were not collected at 48 weeks, limiting conclusions on fibrosis.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)ShowHide
Decision at stakethe choice of pharmacotherapy for adults with non-cirrhotic MASH and F2-F3 fibrosis
…Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.
New evidencecirrhosisportal hypertensionhepatic encephalopathyascites
Clinical takeawayIn patients selected for TIPS for refractory hydrothorax, expect complete response in about 60%; complete response was independently associated with lower mortality (HR 0.30, 95% CI 0.14-0.64), but the 147-patient series had no comparison group without TIPS.
What it foundTIPS achieved complete response (disappearance of symptoms and no further thoracenteses) in 60% of patients with refractory hepatic hydrothorax, with mortality rates of 1.54, 5.34, and 11.4 deaths per 100 patient-months in complete, partial, and no response groups, respectively.
ContextThis study provides evidence supporting TIPS as a potential option for refractory hepatic hydrothorax, though further research is needed to confirm its role in improving survival outcomes.
Emergingsuggested applicable standard· AASLD, 'Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis', Hepatology 2024 (PMID 37870298) - current AASLD guidance for the portal-hypertension context in which TIPS is indicated. Procedure-specific: AASLD 'The Role of TIPS in the Management of Portal Hypertension' (Boyer & Haskal), Hepatology 2010, doi 10.1002/hep.23383.ShowHide
TIPS is a percutaneous interventional-radiology procedure that creates a covered (PTFE-preferred) shunt between portal and hepatic veins to decompress portal hypertension, indicated for refractory ascites (Child-Pugh A/B, MELD <18), refractory variceal hemorrhage, EARLY/pre-emptive placement within 72 h for Child-Pugh C ≤13 (or Child-Pugh B with active bleeding) at index EGD, Budd-Chiari syndrome, and select other decompensation states.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
TIPS is a percutaneous interventional-radiology procedure that creates a covered (PTFE-preferred) shunt between portal and hepatic veins to decompress portal hypertension, indicated for refractory ascites (Child-Pugh A/B, MELD <18), refractory variceal hemorrhage, EARLY/pre-emptive placement within 72 h for Child-Pugh C ≤13 (or Child-Pugh B with active bleeding) at index EGD, Budd-Chiari syndrome, and select other decompensation states. HVPG is measured pre/post with a target reduction ≥20% or HVPG ≤12 mmHg. All patients require pre-procedure cardiac/pulmonary/renal/LT evaluation. Post-procedure encephalopathy prophylaxis (e.g., lactulose and/or rifaximin) should be individualized based on risk factors such as prior HE, age >65, or severe liver dysfunction, with Doppler surveillance for stent dysfunction.
Tizzani M … “TIPS for refractory hydrothorax in cirrhosis” study investigators team · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyretrospective · n=108 · Nov 14, 2026 · Dig Liver Dis · IF 4.2
Clinical takeawayHigh serum urea, high neutrophil count and low platelet count marked higher 30-day mortality risk in SFP; antifungal timing and choice were not studied, and non-albicans Candida showed notable azole resistance.
What it foundSpontaneous fungal peritonitis (SFP) had higher mortality than fungiascites (29.8% vs 13.7%, p=0.045) and spontaneous bacterial peritonitis (29.8% vs 7.0%, p=0.002). A nomogram incorporating serum urea (>18 mmol/L), neutrophil count (>10 × 109/L), and platelet count (<75 × 109/L) may facilitate early assessment of 30-day mortality.
ContextThis study highlights the poorer prognosis of SFP compared to bacterial ascitic infections, refining the understanding of fungal ascitic infections in cirrhosis.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases, 'Guidelines on the Management of Adult Patients with Ascites Due to Cirrhosis', 2021ShowHide
Perform diagnostic paracentesis in any cirrhotic with ascites and infection risk; an ascitic PMN ≥250 cells/μL diagnoses SBP and mandates empiric IV antibiotics ASAP, ceftriaxone 2 g IV daily for community-acquired disease (broader pip-tazo/carbapenem for nosocomial). Administer albumin (1.5 g/kg day 1, 1 g/kg day 3) to patients with serum creatinine >1 mg/dL, BUN ≥30 mg/dL, or bilirubin ≥4 mg/dL to reduce HRS and mortality. Confirm response with a repeat paracentesis at 48 h (adequate = PMN drop ≥25%), distinguish secondary peritonitis by Runyon criteria, and start indefinite secondary prophylaxis (norfloxacin/ciprofloxacin/TMP-SMX) after an episode.
Li X … Huang L · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
Hepatologyprospective cohort · n=430 · Nov 9, 2026 · Hepatology · IF 18.0
New evidencecirrhosisalcohol-associated liver diseasehealth servicesartificial intelligence
Clinical takeawayRemote management with vital-sign and symptom transmission and 24/7 virtual nursing is a candidate post-discharge strategy, especially with CLIF-C AD ≥60 or alcohol-associated liver disease; the evidence is an observational three-cohort comparison with IPTW adjustment.
What it foundCiRPM was associated with fewer 90-day liver-related readmissions than contemporary controls (39% vs 58%; HR 0.57, p=0.01), with a trend versus historical controls (39% vs 52%; HR 0.67, p=0.07); associations were stronger with CLIF-C AD ≥60 (HR 0.43 and 0.51).
ContextThis supports targeted remote management as a scalable post-discharge strategy, refining prior evidence on telemedicine in cirrhosis by identifying high-benefit subgroups.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
New evidencehepatocellular carcinomaliver transplant
Clinical takeawayConsider AFP levels and Milan criteria at LT when assessing HCC recurrence risk in ICI-treated patients, compared to those with AFP<20 and within Milan criteria. For rejection risk, weigh non-HBV etiology, irAEs, younger age, and shorter ICI washout periods, compared to HBV etiology, absence of irAEs, older age, and longer washout periods. Monitor for severe rejection and HCC recurrence, as these are associated with shorter OS.
What it foundHCC recurrence risk was higher with AFP≥20 (aSHR=2.14) and being outside Milan criteria at LT (aSHR=2.17), while severe rejection (aHR=6.09) and HCC recurrence (aHR=15.9) were associated with shorter OS.
ContextThis study provides new evidence on factors influencing post-LT outcomes in ICI-treated HCC patients, refining understanding of recurrence and rejection risks, including severe rejection and HCC recurrence as significant predictors of shorter OS.
Measured against the standard of care· AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834)ShowHide
Decision at stakeuse of immune checkpoint inhibitors before liver transplantation for HCC
…Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case.…It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case. Also surveil selected non-cirrhotic chronic HBV carriers: Asian men >40 and women >50 from endemic regions, people of African origin at younger ages, family history of HCC, or high viral load/active hepatitis. AGA 2026 endorses PAGE-B (intermediate/high risk at ≥10) and REAL-B to stratify these patients. Patients with HCV cirrhosis stay in surveillance after SVR. Patients without cirrhosis from other causes are NOT surveilled because incidence is too low (≤F3 fibrosis, MASLD without cirrhosis, HCV cured before cirrhosis), though fibrosis staging uncertainty warrants individual discussion. CT/MRI are not routine surveillance tools. Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. Multicancer blood detection tests should not be used. AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. Recall per AASLD 2023: AFP ≥20 ng/mL or a rising AFP (doubling, or a rise on two consecutive tests even below 20), any ultrasound observation ≥1 cm, or an inadequate ultrasound triggers multiphasic contrast CT or MRI read with LI-RADS. Treatment per AASLD 2023 is BCLC-linked: resection, ablation or transplant within Milan criteria for very-early/early disease, TACE and other locoregional therapy for intermediate disease, systemic therapy for advanced disease. Preferred first-line systemic therapy in Child-Pugh A is atezolizumab+bevacizumab or durvalumab+tremelimumab (STRIDE); sorafenib, lenvatinib or durvalumab monotherapy are the alternatives. BEACON-HCC (AASLD/HCC-LIVE, Hepatology, online August 2026) is a modified-Delphi North American consensus framework for treatment allocation. It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it. In its 29-case pilot it matched multidisciplinary decisions 96.6% of the time and BCLC 2025 72.4% of the time. Under BEACON-HCC, macrovascular invasion does not automatically mean systemic therapy, and EBRT/SBRT and TARE are primary options. Continue post-treatment surveillance with contrast-enhanced cross-sectional imaging early after curative therapy.
LIFT-HCC Investigators … Yang JD · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatologyretrospective · n=994 · Nov 10, 2026 · J Hepatobil Pancreat Sci · IF 3.8
New evidenceartificial intelligencehepatocellular carcinoma
Clinical takeawayNo clinical action yet: the model requires external validation and integration into clinical workflows.
What it foundAn AI-based preoperative model predicted emergency conversion in MILR with AUC 0.79 (95% CI, 0.72-0.86), stratifying patients into four risk groups with conversion rates of 7.3%, 9.5%, 16.0%, and 37.7%.
ContextThis study addresses a gap in preoperative prediction tools for emergency conversion in MILR, refining risk stratification beyond prior studies that did not distinguish emergency from elective conversion. The model was developed and validated in patients undergoing MILR for hepatocellular carcinoma.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Lee B … Joo H · Journal of Hepato-Biliary-Pancreatic Sciences · IF 3.8 · PubMed ↗Permalink
Hepatologyprospective cohort · Nov 13, 2026 · J Hepatology · IF 40.1
Clinical takeawayNo clinical action yet: a mechanistic finding in mice and in vitro models.
What it foundAquitalea magnusonii translocated across the intestinal barrier, producing 12 ACLF-associated metabolites and increasing inflammation and fibrosis via TLR2/TLR4 activation in vitro and in vivo.
ContextChallenges the focus on gut commensals alone in chronic liver disease, suggesting environmental bacteria may also contribute to disease progression.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Tyc O … Schierwagen R · Journal of Hepatology · IF 40.1 · PubMed ↗Permalink
Hepatologysystematic review · Nov 11, 2026 · BMC Gastro · IF 2.5
Clinical takeawayNo clinical action yet: this is a scoping review with limited direct human evidence; multicentre validation and harmonised assays are needed before clinical use.
What it foundCirculating miR-4651 discriminated AFB1-positive HCC with an AUROC of 0.85, 78.1% sensitivity, and 92.1% specificity in a human study.
ContextThis review highlights the scarcity of direct human evidence linking AFB1 exposure, microRNA dysregulation, and HCC, despite mechanistic plausibility.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Alaka OO … Ayoade F · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink
Hepatologyprospective cohort · n=406 · Nov 10, 2026 · BMC Gastro · IF 2.5
Clinical takeawayNo clinical action yet: a mechanistic finding in a cross-sectional study without evidence of causality or therapeutic implications in humans.
What it foundActivin A levels were higher in patients with steatosis and fibrosis (0.400 ng/mL vs. 0.285 ng/mL, P = 0.036) and strongly correlated with liver stiffness (ρ = 0.696, P < 0.001) in cirrhosis.
ContextThis study adds to conflicting evidence on activin A's role in steatotic liver disease, suggesting it may be a biomarker of fibrosis severity in cirrhosis.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), Kaplan DE, Ripoll C, Thiele M, et al. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis." Hepatology. 2024;79(5):1180-1211.ShowHide
Decision at stakerisk-stratify compensated advanced chronic liver disease with non-invasive tests
…Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy.…
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standardShowHide
Scope: this primary document covers portal hypertension and varices in cirrhosis ONLY. Everything else in the current entry (HCC surveillance, transplant referral, nutrition, vaccination, ascites/SBP/HE/HRS/ACLF management) belongs to the separate documents listed as supporting sources and must not be attributed to this guidance. Risk-stratify compensated advanced chronic liver disease (cACLD) with non-invasive tests before defaulting to endoscopy. By vibration-controlled transient elastography, liver stiffness (LSM) under 10 kPa excludes cACLD, 10 to 14.9 kPa is suggestive and warrants further testing, and 15 kPa or above rules cACLD in. Clinically significant portal hypertension (CSPH, i.e. HVPG above 10 mm Hg) is ruled in non-invasively by LSM at or above 25 kPa alone, or LSM 20 to 24.9 kPa with platelets below 150 x 10^9/L, or LSM 15 to 19.9 kPa with platelets below 110 x 10^9/L. Where spleen stiffness measurement is available, values below 21 kPa argue against CSPH and above 50 kPa argue for it. These non-invasive cutoffs are conditional probability thresholds, not universal diagnostic rules, and hold only when their derivation conditions are met. They were established in compensated advanced chronic liver disease of viral (treated or untreated HBV/HCV), alcohol-related, or non-obese (BMI under 30) MASLD etiology, and are not validated for and should not be applied to cholestatic (e.g. PBC, PSC), vascular, or other etiologies, in which different cutoffs apply. They also require a technically reliable liver stiffness measurement by vibration-controlled transient elastography, fasting, at least 10 valid acquisitions, and an IQR/median ratio below 30 percent, and are confounded by factors that raise liver stiffness independently of fibrosis, including ALT flares or acute hepatitis, extrahepatic cholestasis, hepatic congestion (right heart failure), and recent food intake; Baveno VII recommends confirming an LSM-based rule-in on a repeat measurement obtained on a separate day. The spleen stiffness cutoffs apply only to a dedicated 100 Hz spleen module, carry a higher technical failure rate, are machine-dependent, and are not interchangeable with values obtained using the standard 50 Hz liver probe. Where these population or acquisition conditions are not met, the numeric thresholds do not reliably classify CSPH, and HVPG measurement or endoscopy is required rather than a non-invasive determination. Preserve the gray zone: LSM 15 to 25 kPa without a qualifying platelet count is explicitly indeterminate (roughly 40 to 60 percent of cACLD patients) and calls for HVPG and/or endoscopy rather than assumption in either direction. Once CSPH is established, offer a non-selective beta-blocker, carvedilol preferred at 12.5 mg/day, to lower portal pressure and prevent FIRST decompensation, on the strength of PREDESCI. This is a treat-the-pressure strategy rather than a treat-the-varices one: because a patient already on NSBB for CSPH would not have management changed by the finding, screening endoscopy becomes unnecessary for most such patients. Screening EGD is still indicated where elastography is unavailable, technically difficult, or gives discordant results, and for patients who do not meet non-invasive criteria. Standard beta-blocker contraindications (severe asthma, advanced heart block, bradyarrhythmias) continue to apply. For varices needing treatment managed endoscopically, band ligation is repeated every 2 to 4 weeks until obliteration, with surveillance endoscopy at 6 months and annually thereafter. Gastric/cardiofundal varices are treated with cyanoacrylate injection or EUS-guided coil embolization rather than banding, with hepatology involvement. In acute variceal hemorrhage, consider preemptive (early) TIPS within 24 to 72 hours in high-risk patients: Child-Turcotte-Pugh class B with score above 7 and active bleeding at endoscopy despite vasoactive therapy, or CTP class C with score 10 to 13. Keep the document's own qualifier: there is no established universal MELD or CTP cutoff at which TIPS is mandatory, and the decision is case-by-case with hepatology consultation. Statin use in compensated cirrhosis is NOT a recommendation traceable to this document; the current entry's statin sentence needs its own source or removal. Verification note: the Hepatology full text is paywalled (402/403 on direct fetch). Document identity, title, year, volume, pages and authorship were confirmed via Crossref and PubMed metadata; the numeric thresholds above were corroborated from two independent peer-reviewed commentaries on this specific guidance and match the Baveno VII rule-of-five, but were not read verbatim from the primary PDF. A human should confirm the exact guidance-statement wording against the full text before this entry is treated as quotation-grade.